Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ipilimumab + Nivolumab & Melanoma (cutaneous), Ipilimumab + Nivolumab is approved by both the FDA and EMA for advanced Melanoma (cutaneous) including Melanoma (cutaneous) (BRAF m)
The clinical phase III trial, identified as NCT01844505 or CheckMate 067, presented significant findings. These results, spanning 6.5 years, highlighted the longest median overall survival (OS) recorded in a phase III melanoma trial to date. Additionally, it marked the first re…